Technology | Contrast Media | August 05, 2019

Barium sulfate approval completes NDA Program of the Varibar line of imaging agents for use in modified barium swallow studies

Bracco Receives FDA Approval for Varibar Thin Liquid for Oral Suspension

August 5, 2019 — Bracco Diagnostics Inc. announced U.S. Food and Drug Administration (FDA) approval for Varibar Thin Liquid (barium sulfate) for oral suspension, which is indicated for modified barium swallow (MBS) studies. The contrast agent is used to detect and assess the type and severity of swallowing disorders also known as dysphagia.

In the U.S., approximately 13 million (1 in 25) Americans suffer from dysphagia.1  Dysphagia varies in severity and can be caused by a number of conditions and diseases, such as stroke, traumatic brain injury, dementia, Parkinson's disease, multiple sclerosis, and treatment of head and neck cancer or trauma.1 The most common complications are aspiration pneumonia, malnutrition and dehydration.2  Aspiration pneumonia is a subset of pneumonia caused by inhalation of substances such as liquid and/or food into the lungs when the swallowing mechanism does not function properly. It requires hospitalization and is associated with 10 percent in-hospital mortality and high hospitalization cost, estimated at approximately $30,000 per case.3

An MBS study is performed by a team comprised of a speech language pathologist (SLP) and a radiologist to identify issues with a patient's swallowing mechanism.  During an MBS, the patient swallows products with different thicknesses containing a barium X-ray contrast agent, while the radiologist takes fluoroscopic X-ray images.

Varibar Thin Liquid (barium sulfate) oral suspension requires reconstitution prior to use.

For more information: www.imaging.bracco.com

References

1. Bhattacharyya N. The prevalence of dysphagia among adults in the United States. Otolaryngology–Head and Neck Surgery 2014; 151: 765–769

2. Schindler A, Ginocchio D, Ruoppolo G. What we don't know about dysphagia complications? Rev Laryngol Otol Rhinol (Bord) 2008;129:75-88

3. Wu C-P., Chen Y-W., Wang M-J., et al. National Trends in Admission for Aspirational  Pneumonia in the United States, 2002-2012; Annals ATS 2017, 14: 874-879

Related Content

News | PACS

November 24, 2021 — Konica Minolta Healthcare Americas Inc. announced new features and functionality for the Exa ...

Time November 24, 2021
arrow
News | Breast Imaging

November 24, 2021 — Hologic Inc. will showcase its extensive portfolio of breast and skeletal health products, including ...

Time November 24, 2021
arrow
News | Flat Panel Displays

November 24, 2021 — The rise of digital imaging technology has quickly changed the way in which patient data are used ...

Time November 24, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 24, 2021 — Royal Philips announced new AI-enabled innovations in MR imaging launching at the Radiological ...

Time November 24, 2021
arrow
News | Coronavirus (COVID-19)

November 24, 2021 — Significant decreases in CT imaging for cancer persisted even after the peak of the COVID-19 ...

Time November 24, 2021
arrow
News | Lung Imaging

November 23, 2021 — Median Technologies announces new outstanding performance of its lung cancer screening (LCS) CADx1 ...

Time November 23, 2021
arrow
News | Artificial Intelligence

November 23, 2021 — Laurel Bridge Software Inc., a provider of imaging software solutions that enables health systems to ...

Time November 23, 2021
arrow
News | Artificial Intelligence

November 23, 2021 — The results of a unique two-tiered brain tumor AI challenge were announced today by the Radiological ...

Time November 23, 2021
arrow
News | Radiology Business

November 23, 2021 — Guerbet LLC, the U.S. affiliate of Guerbet, a global leader in medical imaging, is pleased to be ...

Time November 23, 2021
arrow
News | Artificial Intelligence

November 23, 2021 — Royal Philips announced a collaboration with U.S.-based MedChat to integrate MedChat’s live chat and ...

Time November 23, 2021
arrow
Subscribe Now